Platform Start-Up Anaphore And Mitsubishi Tanabe Ink Deal For Autoimmune Therapies

Anaphore's novel Atrimer platform creates trivalent protein drugs to bind all three domains on trivalent ligands and receptors, a presumed advantage over two-armed antibodies.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet